DAP10 Predicted the Outcome of Pediatric B-Cell Acute Lymphoblastic Leukemia and Was Associated with the T-Cell Exhaustion
Table 1
Clinical data of the groups divided by immune score and stromal score.
Immune-Ha
Immune-L
Stromal-H
Stromal-L
WBC count
53.1 ± 7.5
25.2 ± 9.7
0.419
56.2 ± 11.3
44.0 ± 7.2
0.779
WBC >50
36.4% (32/88)
11.1% (1/9)
0.121
38.5% (20/52)
33.3% (15/45)
0.378
Age
7.4 ± 5.0
7.9 ± 4.8
0.339
7.8 ± 5.1
7.4 ± 4.8
0.438
Age ≥10
33.0% (29/88)
33.3% (3/9)
0.623
32.7% (17/52)
33.3% (15/45)
0.559
BCR-ABL1
3.4% (3/88)
0.0% (0/9)
0.744
5.8% (3/52)
0.0% (0/45)
0.150
CNS3b
3.4% (3/88)
0.0% (0/9)
0.744
5.8% (3/52)
0.0% (0/45)
0.150
High risk
58.0% (51/88)
44.4% (4/9)
0.332
61.5% (32/52)
51.1% (23/45)
0.204
Relapse
71.6% (63/88)
77.8% (7/9)
0.518
63.5% (33/52)
82.2% (37/45)
0.033
Tri 4/10
12.8% (10/78)
0.0% (0/9)
0.315
10.9% (5/46)
12.2% (5/41)
0.554
TEL/AML1
11.6% (8/69)
11.1% (1/9)
0.723
11.1% (4/36)
11.9% (5/42)
0.599
TCF3/PBX1
9.0% (6/67)
11.1% (1/9)
0.602
2.4% (1/42)
17.6% (6/34)
0.028
For quantitative data, the results were presented as mean ± SEM; for qualitative data, the results were presented as percentage (positive/all). (a) Immune-H, high immune score group; Immune-L, low immune score group; Stromal-H, high stromal score group; Stromal-L, low stromal score group. (b) CNS3, CNS3 at diagnosis.
